Geographic Atrophy

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.

A look at podium presentations on GA research at ASRS 2025.

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next steps in ongoing research.

Catch up on recent advancements in retina care, including new therapies for age-related macular degeneration and macular telangiectasia, enhancing patient outcomes.

Dr. Nimesh A. Patel reveals key findings on pegcetacoplan and anti-VEGF treatments for geographic atrophy and neovascular AMD at ASRS 2025.

Jay Chhablani, MD, presented the phase 1/2 clinical trial data for OCU410, at the 2025 annual meeting of the American Society of Retina Specialists.

Vonaprument has received fast track designation from the US Food and Drug Administration.

SAR446597 is a one-time intravitreal gene therapy treatment for the treatment of geographic atrophy

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

Preliminary results of PST-611-CT1 are anticipated early 2026, subject to patient recruitment.

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive retinal disease.

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing reliance on low vision centers.

The trial treated 9 patients in 3 sequential, ascending dose-level (DL) cohorts.